Calidi Biotherapeutics Announces FDA Clearance Of The Northwestern University IND Application For The CLD-101 Clinical Trial In High-Grade Glioma; Phase 1/2 Trial Expected To Initiate In Q1 Of 2025
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics has announced that the FDA has cleared Northwestern University's IND application for the CLD-101 clinical trial targeting high-grade glioma. The Phase 1/2 trial is expected to begin in Q1 2025.
September 30, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calidi Biotherapeutics has received FDA clearance for a clinical trial application for CLD-101, a treatment for high-grade glioma. This regulatory milestone paves the way for a Phase 1/2 trial starting in Q1 2025.
The FDA clearance is a significant regulatory milestone for Calidi Biotherapeutics, indicating progress in their clinical development pipeline. This news is likely to positively impact the stock as it shows advancement towards a potential new treatment for high-grade glioma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90